Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
WARREN, N.J., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Tevogen Bio Holdings Inc. ( "Tevogen" or the "Company" ) ( Nasdaq: TVGN ) , announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations and Service Providers.
Why Johnson & Johnson ( JNJ ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Stryker's Robotics and Global Gains Offset by Macro Concerns
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs - AstraZeneca ( NASDAQ:AZN ) , Biogen ( NASDAQ:BIIB )
Johnson & Johnson JNJ is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration. J&J announced its investment on Thursday, as reported by Reuters.
5 Vanguard ETFs to Buy With $500 and Hold Forever
These exchange-traded funds can provide a solid foundation for your portfolio.
3 Stable Dividend-Paying Stocks That Are Perfect for Retirees
Names you've heard of with track records to love.
How Do Investors Really Feel About Johnson & Johnson? - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson's JNJ short percent of float has fallen 6.58% since its last report. The company recently reported that it has 17.14 million shares sold short, which is 0.71% of all regular shares that are available for trading.
Congressional Trading Report: Rep. Thomas Kean Sold Over $31K In Johnson & Johnson Stock - Check Point Software ( NASDAQ:CHKP ) , Johnson & Johnson ( NYSE:JNJ )
August 20, 2025 records indicate that Representative Thomas Kean filed a sale of Johnson & Johnson JNJ, valued between $31,003 and $115,000. According to the August filing, the transaction occurred on July 31, 2025. Currently, Johnson & Johnson shares are trading up 0.16% at $179.13.
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
Sender Buys Into the Turnaround Story at Kenvue
According to an SEC filing published August 15, 2025, Sender Co & Partners, Inc. increased its position in Kenvue ( NYSE:KVUE ) by 530,717 shares. The estimated trade value, based on the period's average share price, was approximately $12.08 million.
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - Aligos Therapeutics ( NASDAQ:ALGS )
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Aligos Therapeutics, Inc.
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ...
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer - Rezolute ( NASDAQ:RZLT )
REDWOOD CITY, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Rezolute, Inc. RZLT ( "Rezolute" or the "Company" ) , a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism ( HI ) , today announced the appointment of Sunil Karnawat as Chief Commercial Officer, ...
Why Is Carlsmed Stock Gaining Monday? - Carlsmed ( NASDAQ:CARL )
CMS grants NTAP reimbursement of up to $21,125 for Carlsmed's spine implants. BofA forecasts 66% revenue growth in 2025, Buy rating with $16 target. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here → Carlsmed Inc.
Investors Heavily Search Johnson & Johnson ( JNJ ) : Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
SOMERSET, N.J., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Legend Biotech Corporation ( NASDAQ: LEGN ) ( Legend Biotech ) , a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately.
Should WisdomTree U.S. High Dividend ETF ( DHS ) Be on Your Investing Radar?
Style Box ETF report for ...
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
These companies have successfully navigated similar obstacles before.
Is This the Best Dividend King Stock to Buy Right Now?
While it's been a consistent performer for decades, this company still has a massive growth opportunity.
These Are the 3 Smartest Dividend Stocks Today
These three dividend stocks offer steady income and a history of delivering through thick and thin.
This Red-Hot Vanguard ETF Just Hit an All-Time High. Here's Why It's Still Worth Buying in August.
The Vanguard Dividend Appreciation ETF has an excellent balance of growth, income, and value stocks.
Why Is Johnson & Johnson ( JNJ ) Up 7.2% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MeiraGTx Sales Jump 1,133 Percent
MeiraGTx Plc ( NASDAQ:MGTX ) , a biotechnology company specializing in gene therapies for neurodegenerative, ocular, and glandular disorders, released its second quarter results on August 14, 2025. The key news centered on a sizable year-over-year revenue gain ( GAAP ) -reflecting progress in ...
Palantir Is Now the 19th Largest Public Company. Is This House of Cards About to Come Crashing Down?
Palantir Technologies is priced for perfection. Unfortunately, no situation on Wall Street is ever perfect.
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( NASDAQ: LVTX, "LAVA," or the "Company" ) , a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced ...
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and ...
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, August 13, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of ...
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts ...
ASCM Houston Chapter Presents "Navigating the Future - A Port of Houston Update" at Houston Maritime Center & Museum
HOUSTON, Aug. 13, 2025 /PRNewswire/ -- The ASCM Houston Chapter will host an exclusive professional development event, Navigating the Future - A Port of Houston Update, on Thursday, August 21, from 5:30 PM to 7:30 PM at the Houston Maritime Center & Museum, 2940 Riverby Road, Suite 200, Houston, ...
Healthy Returns: FDA launches program to streamline creation of new U.S. drug manufacturing sites
A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Zacks Industry Outlook Highlights Globant and NetEase
Globant and NetEase stand out in a strengthening software services industry, leveraging AI, subscriptions, and global reach for growth.
XOMA Revenue Jumps 39% in Fiscal Q2
XOMA ( NASDAQ:XOMA ) , a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company's revenue ( GAAP ) reached $13.1 million for Q2 2025, surpassing analyst GAAP estimates of $9.39 million.
Mersana Misses Fiscal Q2 Revenue Target
Mersana Therapeutics ( NASDAQ:MRSN ) , a clinical-stage biotech specializing in antibody-drug conjugates ( ADCs ) for cancer, reported its second quarter results on August 13, 2025. The company's update featured continued clinical development progress and the start of new expansion cohorts in its ...
Palantir Technologies Stock: Will It Hit a $500 Billion Valuation This Year?
The data analytics stock is up over 140% this year.
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.
Vicarious Surgical Narrows Loss in Q2
Vicarious Surgical ( NYSE:RBOT ) , a developer focused on next-generation robotic technology for minimally invasive surgery, released its second quarter 2025 financial results on August 12, 2025. The standout news: the company posted a narrower non-GAAP net loss than analysts anticipated, with an ...
Johnson & Johnson EVP Sells JNJ Shares Worth $3 Million
John C. Reed, Executive Vice President, Innovative Medicine and R&D of Johnson & Johnson ( NYSE:JNJ ) , executed an open market sale of 19,137 shares as disclosed in a Form 4 filed July 18, 2025.How does this transaction compare to John C.
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners.
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.
5 Dividend Stocks to Hold for the Next 5 Years
These top dividend stocks should deliver strong total returns over the next half-decade.
2 High-Yielding ETFs That You Can Rely on for Recurring Income
The funds listed here offer a good mix of safety, diversification, and dividends.
3 Stocks Retirees Should Absolutely Love
These stocks check off all the boxes for investors no longer receiving a paycheck.
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Genmab ( NASDAQ:GMAB )
Epcoritamab combo reduced the risk of disease progression or death by 79% in the Phase 3 FL trial. Genmab raised its 2025 revenue outlook to $3.5-$3.7 billion after Q2 beat and 19% Y/Y growth. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →
Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-Free
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
Why it's so difficult to manufacture in the U.S.
Factories fled the U.S. for cheaper labor abroad. Some companies, like Guardian Bikes, are testing whether "Made in America" still works.
RxSight ( RXST ) Q2 Loss Beats Estimates
RxSight ( NASDAQ:RXST ) , a U.S.-based ophthalmic medical device company, reported its second quarter 2025 financial results on August 7, 2025. The most notable developments in the release were a lower-than-expected GAAP revenue outcome alongside a marked improvement in profitability metrics, ...
